Science & Enterprise subscription

Follow us on Twitter

  • The World Solved the Ozone Problem. It Can Solve Climate Change. https://t.co/BVlMgafyiM
    about 1 day ago
  • A solid majority of Americans now says that climate change affects their communities, a finding that could affect f… https://t.co/FeSjrqpv7t
    about 2 days ago
  • New post on Science and Enterprise: Infographic – Most in US Say Climate Change Affects Them https://t.co/5N2p07v38r #Science #Business
    about 2 days ago
  • Many thanks @deansguide for the shout-out and all of your good work for lung health. I just report on stuff. Enjoy… https://t.co/nrNcveHCJM
    about 3 days ago
  • A company developing 3-D printed outer ear tissue received a rare pediatric disease designation on its treatment de… https://t.co/Iya45fwEl2
    about 3 days ago

Please share Science & Enterprise

Sanofi to Cut Genzyme Massachusetts Research Staff

Closed sign (Artaxerxes, Wikimedia Commons)The French pharmaceutical maker Sanofi says it will reduce its research workforce employed in and around Boston, as a result of its acquisition of Genzyme Corporation a year ago. Sanofi confirmed the cuts today in a statement to the industry Web site Fierce Biotech.

Genzyme, headquartered in Cambridge, Massachusetts, was acquired by Sanofi last year for some $20 billion. The company, which kept its separate identity within the Sanofi structure, has a large presence in the Massachusetts, with eight separate locations in the state, in addition to its headquarters, listed on its Web site.

The company’s statement did not specify the number of positions eliminated or relocated. “As part of the integration process between Sanofi and Genzyme, R&D activities were reviewed and assessed,” says the statement. “On January 31, 2012, the results of the review of U.S. R&D Genzyme activities were announced, including synergies that unfortunately make some positions redundant.”

Sanofi says in the statement that the company will continue investing and hiring in Massachusetts for its work on multiple sclerosis, as well as its manufacturing functions. Last week, FDA approved the Genzyme plant making the drug Fabrazyme to treat Fabry disease, a rare genetic disorder. Shortages of Fabrazyme had been reported, which the company expects the new plant will help erase over the course of this year.

Read More: Sanofi-aventis Acquires Genzyme in $20.1B Deal

*     *     *

Please share Science & Enterprise ...
error

Comments are closed.